Survival
RECURRENCES, LYMPH NODE METASTASES, METASTATIC DISEASE, PULMONARY METASTASES, LIVER METASTASIS
As of January 31, 2022, the median follow-up time was 51.2 months for the 46 patients who received R0 resection, with local recurrences confirmed in 3 (6.5%) patients. Nine of 46 (19.6%) patients developed metastatic disease, including 6 with pulmonary metastases, 1 liver metastasis and 2 retroperitoneal lymph node metastases. Until the last follow-ups, the median DFS and OS had not been reached while the 3-year DFS and OS rates were 75.8% and 86.8%, respectively (Fig. Kaplan–Meier estimate of (The status of MRF and EMVI on MRI at baseline and after nCT were evaluated retrospectively. These results were compared with pathological status after surgery (Table Characteristics evaluated by MRI at baseline and after neoadjuvant chemotherapy and the pathological characteristics (